Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “SION”

1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,496
Index total 30,257
Page 9 / 63

Quick answer

This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,496 results for “SION” · 30,257 patents in full index Clear search

  1. US 11788077

    Polynucleotides encoding optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome

    Precision BioSciences, Inc. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted

  2. US 11788141

    MVD as epigenetic marker for the identification of immune cells, in particular CD56+ NK cells

    Precision for Medicine GmbH · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted

  3. US 11781143

    Modulators of PNPLA3 expression

    Ionis Pharmaceuticals, Inc. · Granted Oct 10, 2023 · Expires Oct 5, 2043

    granted

  4. US 11771723

    Bifidobacterium longum NCIMB 41676

    PrecisionBiotics Group Limited · Granted Oct 3, 2023 · Expires Sep 28, 2043

    granted

  5. US 11767325

    Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators

    PRAXIS PRECISION MEDICINES, INC. · Granted Sep 26, 2023 · Expires Sep 21, 2043

    granted

  6. US 11767367

    Monoclonal antibody neo-201 for the treatment of human carcinomas

    PRECISION BIOLOGICS, INC. · Granted Sep 26, 2023 · Expires Sep 21, 2043

    granted

  7. US 11761003

    Adeno-associated virus for activating RNA-NEAT1 over-expression and applications thereof

    EYE INSTITUTE OF SHANDONG FIRST MEDICAL UNIVERSITY · Granted Sep 19, 2023 · Expires Sep 14, 2043

    granted

  8. US 11753630

    Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene

    Precision BioSciences, Inc. · Granted Sep 12, 2023 · Expires Sep 7, 2043

    granted

  9. US 11753408

    Compounds and method for blocking transmission of malarial parasite

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Sep 12, 2023 · Expires Sep 7, 2043

    granted

  10. US 11753644

    Compounds and methods for reducing IFNAR1 expression

    Ionis Pharmaceuticals, Inc. · Granted Sep 12, 2023 · Expires Sep 7, 2043

    granted

  11. US 11744800

    Methods of use of emulsion formulations of an NK-1 receptor antagonist

    Heron Therapeutics, Inc. · Granted Sep 5, 2023 · Expires Aug 31, 2043

    granted

  12. US 11731978

    3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator

    PRAXIS PRECISION MEDICINES, INC. · Granted Aug 22, 2023 · Expires Aug 17, 2043

    granted

  13. US 11731966

    Compounds and their methods of use

    PRAXIS PRECISION MEDICINES, INC. · Granted Aug 22, 2023 · Expires Aug 17, 2043

    granted

  14. US 11730793

    Sustained release formulations using non-aqueous emulsions

    REGENERON PHARMACEUTICALS, INC. · Granted Aug 22, 2023 · Expires Aug 17, 2043

    granted

  15. US 11731976

    3-(ethoxydifluoromethyl)-6-(5-fluoro-6-(2,2,2-trifluoroethoxy)pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyridine as an ion channel modulator

    PRAXIS PRECISION MEDICINES, INC. · Granted Aug 22, 2023 · Expires Aug 17, 2043

    granted

  16. US 11732265

    Compositions and methods for modulating complement factor B expression

    Ionis Pharmaceuticals, Inc. · Granted Aug 22, 2023 · Expires Aug 17, 2043

    granted

  17. US 11723885

    Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse

    Acurx Pharmaceuticals, Inc. · Granted Aug 15, 2023 · Expires Aug 10, 2043

    granted

  18. US 11723946

    Methods for regulating transcription of multiple genes and expression of multiple targets

    China Medical University · Granted Aug 15, 2023 · Expires Aug 10, 2043

    granted

  19. US 11713462

    Modulation of GYS1 expression

    Ionis Pharmaceuticals, Inc. · Granted Aug 1, 2023 · Expires Jul 27, 2043

    granted

  20. US 11707536

    Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A

    Takeda Pharmaceutical Company Limited · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted

  21. US 11701355

    Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)

    TENAX THERAPEUTICS, INC. · Granted Jul 18, 2023 · Expires Jul 13, 2043

    granted

  22. US 11697669

    Hemi-citrate salts of GABA-A positive allosteric modulator and crystalline form thereof

    PRAXIS PRECISION MEDICINES, INC. · Granted Jul 11, 2023 · Expires Jul 6, 2043

    granted

  23. US 11680254

    Engineered meganucleases specific for recognition sequences in the PCSK9 gene

    Precision BioSciences, Inc. · Granted Jun 20, 2023 · Expires Jun 15, 2043

    granted

  24. US 11679159

    Compositions for transfecting resistant cell types

    Precision Nanosystems ULC · Granted Jun 20, 2023 · Expires Jun 15, 2043

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.